Case Study Using Nebulized Isomerized Linoleic Acid (LA) for Outpatient Treatment of Symptomatic COVID-19.
11 Pages Posted: 23 Nov 2020
Date Written: November 19, 2020
We report the resolution of COVID-19 related symptoms in 6 days in two moderate to high risk COVID-19 patients (CDC, 2020) treated with nebulized 0.5 ml 11 mM LA every 4 hours around the clock for 7 days in an outpatient setting. The lipid potassium salt LA is Generally Recognized As Safe (GRAS) by the FDA (Food Additive). We report that in vitro testing of LA 4.4-50.2 mM showed 99% kill-rate of COVID-19 in 2 minutes. Pulmonary symptoms resolved and pulse oximetry levels normalized within the same week of symptom onset, returning to their normal marital relations on day 6. This compares to the median recovery time of two weeks from onset of symptoms for mild, and three to six weeks for severe COVID-19 cases (WHO, 2020). LA with its capacity to provide an affordable intervention within a home environment deserves further study to determine if it reduces severity, length of symptoms, and complications of COVID-19.
Note: Funding: Medical care and products provided to the indigent patients by the author, Sven Jonsson, MD. Funding for virology studies at Institute for Antiviral Research, Utah State University provided by David G. Changaris, MD PSC.
Declaration of Interests: None.
Ethics Approval Statement: Treatment was performed after informed consent of the risks and potential benefits by the patients.
Suggested Citation: Suggested Citation